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Abstract: Multiple efforts have been made to develop small-diameter tissue engineered 
vascular grafts using a great variety of bioreactor systems at different steps of processing. 
Nevertheless, there is still an extensive need for a compact all-in-one system providing 
multiple and simultaneous processing. The aim of this project was to develop a new device 
to fulfill the major requirements of an ideal system that allows simultaneous seeding, 
conditioning, and perfusion. The newly developed system can be actuated in a common 
incubator and consists of six components: a rotating cylinder, a pump, a pulse generator, a 
control unit, a mixer, and a reservoir. Components that are in direct contact with cell 
media, cells, and/or tissue allow sterile processing. Proof-of-concept experiments were 
performed with polyurethane tubes and collagen tubes. The scaffolds were seeded with 
fibroblasts and endothelial cells that were isolated from human saphenous vein segments. 
Scanning electron microscopy and immunohistochemistry showed better seeding success of 
polyurethane scaffolds in comparison to collagen. Conditioning of polyurethane tubes with 
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100 dyn/cm2 resulted in cell detachments, whereas a moderate conditioning program with 
stepwise increase of shear stress from 10 to 40 dyn/cm2 induced a stable and confluent cell 
layer. The new bioreactor is a powerful tool for quick and easy testing of various scaffold 
materials for the development of tissue engineered vascular grafts. The combination of this 
bioreactor with native tissue allows testing of medical devices and medicinal substances 
under physiological conditions that is a good step towards reduction of animal testing. In 
the long run, the bioreactor could turn out to produce tissue engineered vascular grafts for 
human applications “at the bedside”. 




Chronic ischemic heart disease, coronary artery disease, and cardiac infarction are the most 
common causes of death worldwide, accounting for 25.6% of all fatal casualties [1]. They are 
predominantly caused by a restriction of the coronary circulation which is commonly affected by 
atherosclerotic occlusion [2].  
The use of patient’s native veins to replace faulty blood vessels is still the silver bullet in clinical 
practice [3,4]. Although minimal invasive techniques seem to outstrip the conventional vascular 
replacement [5], surgical bypass is still performed in numerous patients [6]. Coronary artery bypass 
grafting (CABG) using intact autologous veins results in less events of stroke, myocardial infarction 
(MI) or repeated revascularization in long-term application compared to percutaneous coronary 
intervention (PCI) [7,8]. The results of the SYNTAX (Synergy between PCI with TAXUS  
(paclitaxel-eluting stents) and Cardiac Surgery) study from 2011 [9,10] permit the identification of 
patients that have a greater benefit from bypass surgery instead of PCI. 
For patients who cannot be treated with PCI and/or for patients who do not possess adequate 
autologous vessel material for CABG, there is still an increasing need for new innovative implants [11]. 
Native vessels and conventional polytetrafluoroethylene (PTFE) grafts show various limitations  
like re-occlusion, aneurysm formation and/or thrombogenicity. Processing techniques for artificial 
grafting aim to overcome these limitations by enabling the development of smaller graft diameters  
(inner diameter < 6 mm) [4,12,13].  
Currently, there are multiple approaches under investigation to develop an ideal graft. Apart from a 
small number of scaffold-free concepts, organic or synthetic, degradable or non-degradable scaffolds 
are in common use [4].  
An untreated surface often leads to rejection, requiring coatings like heparin to avoid occlusion by 
clotting [14] or paclitaxel to suppress hyperplasia [15]. The different coatings have a significant 
positive impact on the performance of the scaffold material, but the integrity of these coatings is 
usually compromised at high flow rates [16]. Another promising strategy is the seeding of the  
graft with endothelial cells (ECs) [17,18]. This unstable cell-matrix-interaction can be supported and 
guaranteed by pre-seeding the new prosthesis with vascular fibroblasts (FBs), which mimic the cellular 
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structure of healthy subjects [19,20]. Various cell sources like stem cells [21], endothelial progenitor 
cells [22] or isolated vascular ECs [23] are under investigation for graft seeding. Depending on their 
origin, stem cells are reported to have a high growth and repair potential in many cases [24–26]. The 
use of embryonic stem cells for therapeutic purposes is subject to ethical and legal concerns, and thus 
they are not currently utilized for tissue engineering investigation. Tumor formation is an actual risk of 
embryonic stem cells due to their indefinite propagation as well as immunologic intolerance caused by 
the allogeneic nature [24,26–28]. Without any ethical concerns, adult stem cells can be derived from 
the patient and are therefore autologous in nature. Additional possible sources are bone marrow, 
peripheral blood, skeletal muscle, and, in the long term, placental cord blood. However, the induced 
transdifferentiation of adult stem cells at the necessary efficiency is infeasible. If these disadvantages 
remain unsolved embryonic and adult stem cells cannot be regarded as standard options for tissue 
engineering [26,27,29]. 
In contrast, autologous differentiated ECs derived from the saphenous vein segments do not require 
any immune suppression and have no carcinogenic potential. This safe cell source comes at the cost of 
an invasive surgical procedure to harvest intact vascular donor tissue [30]. 
In addition to material surface modification, it is known that shear stress and transmural pressure 
influence the shape and biosynthesis of vascular cells. The effects are structural remodeling and 
flattening of ECs as well as activation of signaling cascades [31,32]. If signals are inappropriate or 
missing altogether, cells proliferate only poorly and lose cell-cell contacts and the ability to form 
organized tissues [33,34]. The cells dedifferentiate and no extracellular matrix (ECM) is established. In 
summary, mechanical stress is essential for the achievement of a good quality ECM [35]. 
Due to these essential conditions for the development of a cell-based graft, different bioreactors 
have been developed recently to simulate physiological conditions, such as temperature, blood flow, 
shear stress or mechanical strain. These systems play a crucial role in building tissue engineered 
constructs [36]. They can be used for seeding and conditioning as well as for mechanical stress tests 
under physiological conditions [37]. As a general rule, the development of tissue-engineered implants 
should be realized in a sterile system under stable physiological conditions (shear stress and blood 
flow) [17,31,38,39], which allows for reproducible and low cost processes. Bioreactors should enable 
the observation of different parameters like CO2, nutrients and growth factors to guarantee a good 
manufacturing practice [40]. 
So far, only few research groups have developed bioreactors with the capability to simultaneously 
perform dynamic seeding and pulsatile flow processes of multiple grafts under physiological 
conditions [41–48]. Therefore, the aim of this study was to develop an all-in-one bioreactor (BR) 
offering comparative test results, adjustable process parameters and simple handling. 
2. Experimental Section 
2.1. Bioreactor Development  
2.1.1. Construction 
All parts of the bioreactor (BR) were designed using the computer-aided software CatiaV5R19 
(DassaultSystèmes, Vélizy-Villacoublay, France). Non-electric BR components were manufactured  
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in-house. Parts that are in contact with cell media, cells, and/or tissue were developed such as to allow 
reprocessing. The BR system consists of six components: a seeding cylinder, a rotating mixer, a media 
reservoir, a control unit, a roller pump, and a pulse generator. All parts are assembled on a square 
ground plate made of polyvinylchloride (PVC) with a length l = 400 mm and height h = 15 mm.  
The dimensions allow the actuation of the bioreactor in a standard incubator. 
Seeding Device 
The seeding device (Figure 1) comprises a cylinder filled with cell culture medium surrounding the 
tissue engineered vascular graft (TEVG). In the cylinder, two pairs of fixed vessel cannulas allow a 
simultaneous perfusion of two TEVGs. The housing of the cylinder with an outer diameter D = 65 mm, 
an inner diameter d = 46 mm, an outer height H = 155 mm, and an inner height h = 130 mm is made 
from polymethyl methacrylate (PMMA) and narrows to d = 15 mm at the tip. The cylinder has a guide 
rail (depth = 15 mm, l = 10 mm) to secure the cylinder position on the mixer. At the base, a metric 
thread (M64 × 1.5) is milled to lock the cylinder with a screw cap (D = 73 mm, d = 48 mm, h = 15 mm) 
and a step (depth = 14 mm) with d = 55 mm is created to countersink the integrated scaffold carrier of 
the seeding device. 
Figure 1. Transversal section (a) and top view (b) of the seeding device composed of a 
cylindric housing (1) with screw cap (2). The scaffold carrier with an outlet (3) and  
an inlet (4) is adjusted with four spacers (5) and allows the simultaneous perfusion of two 
tissue engineered vascular grafts (TEVGs) (6). The scaffolds are fixed with vessel cannulas 
(7) while the spacers are fixed with screw nuts (8). Luer-Lock-adapters (9) simplify filling 
processes and connection to the tubing system. 
 
(a) (b) 
The scaffold carrier of the seeding device is composed of an outlet (Figure 1, (3), d = 46 mm,  
h = 28.5 mm with a nose of d = 15 mm, h= 45 mm) and an inlet (Figure 1, (4), d = 55 mm, h = 15 mm 
with a nose of d = 15 mm, h= 15 mm) made of polyoxymethylene (POM). Both elements are 
composed of two parts to generate branched supply channels, shown in detail for the outlet in  
Figures 2 and 3. 
The distance of the inlet and the outlet is regulated by four spacers made of medical grade steel 
(Figure 1, (5), d = 4 mm, h = 150 mm) that are positioned in a radius of 38 mm. The BR channels 
(Figure 1, (1)) with a diameter of 4 mm are arranged parallel in a distance of 10 mm. The Luer-Lock 
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adapters for the vessel grafts are countersunk into the channels. Two rotatable Luer-Lock connectors 
are mounted on the inlet and outlet to allow parallel rotational seeding and perfusion procedures.  
Two additional Luer-Lock connectors are attached to the lid for filling processes. O-rings are used as 
sealing elements to ensure fluid transport without leakage. The scaffold carrier is positioned into the 
seeding cylinder and secured by the closure of the lid. 
Figure 2. Top view (a), bottom view (b) and transversal section (c) of the outer part of the 
outlet with a bore hole (1) for the perfusion media, a bore hole (2) for filling the seeding 
cylinder, a bore hole (4) for the spacers, a thread (3) for screwing the inner part of the 
outlet in place and an indentation (5) to keep a gasket in place. 
 
Figure 3. Top view (a), bottom view (b) and transversal section (c) of the inner part of the 
outlet with a bore hole (1) for perfusion media, a furrow (2) to generate a branched supply 
channel and a thread (3) for screwing the inner part of the outlet in its outer part. 
 
The seeding device has a maximum capacity of 130 mL, depending on the spacer offset. It has an 
outer radius of 65 mm and an overall length of 200 mm with a net weight of 600 g. 
Mixer 
For dynamical rotation the seeding cylinder is placed on the mixer (Figure 4). All external parts of 
the mixer are manufactured from aluminum. The design is based on commercially available roller 
mixers. Two drive shafts with l = 193 mm and narrowing diameters (d = 20 to 6 mm) are mounted on a 
base with a distance of 61.5 mm. Grooved ball bearings (20 × 32 × 7 mm, 6804 2RS) and miniature 
ball bearings (6 × 16 × 15 mm, S696A 2RS) are used for each shaft. The front shaft is driven by a 
wheel (D = 68.5 mm, d = 58.5 mm), which is connected to a gear motor with a belt drive. The back 
shaft is connected with the first shaft by two wheels (D = 38 mm, d = 28.5 mm) and a belt drive.  
a b c
a b c
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The rotation speed of the cylinder is at 13.4 RPM (rounds per minute). Two O-rings on each shaft and 
a guardrail prevent the seeding cylinder from slipping during rotation. A retaining bracket, locked by 
two spring-loaded latches, allows prompt fixation of the seeding cylinder. 
Figure 4. Top view of the mixer (a) and a transversal section through the front shaft (b). 
The mixer is composed of two shafts (1), ball bearings (2, 3), and wheels (4, 5) for rotation. 
An O-ring (6) prevents the seeding cylinder from slipping. A guardrail (7) and a latch  
(8 + 10) secure the seeding cylinder on the mixer. The shafts are assembled on a base (9). 
 
Media Reservoir 
The media reservoir (Figure 5; D = 78 mm, d = 58 mm, H = 110 mm, h = 100 mm) is manufactured 
from PMMA and has a capacity of 220 mL. Two Luer-Lock adapters are fixed to the reservoir wall in 
a distance of 15 mm and 30 mm to the reservoir bottom. The screw cap of the reservoir (D = 80 mm,  
d = 58 mm, H = 14 mm, h = 7 mm) contains four Luer-Lock adapters in a radius of 44 mm. A gasket 
ring secures a tight closure of the reservoir. 
The reservoir is placed in an aluminum stub (D = 89 mm, d = 79 mm, h = 10 mm). An aluminum 
ring (D = 120 mm, h = 6 mm) enables the fixation to the ground plate via screws. The reservoir stub 
provides a gap of 20 mm for M5 Luer-Lock connectors of the reservoir. A M5 Teflon screw on the 
opposite side of the gap secures the position of the reservoir. 
A peristaltic roller pump (WELCO Co. Ltd., Tokyo, Japan) is used for circulating perfusion through 
the BR. The speed of this pump is regulated by a speed controller (10 A, Conrad Electronic SE, Hirschau, 
Germany) with a potentiometer (wire-wound linear, 10 kΩ, 2 W, Conrad Electronic SE, Hirschau, 
Germany). The pump is combined with an eccentric device (pulser) driven by a DC-motor, which 
compresses the scaffold tubes periodically, resulting in a pulse right in front of the seeded scaffolds at 
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Figure 5. Transversal section (a) and top view (b) of the media reservoir of the bioreactor 
with a stub (1) screwed to the ground plate (2), a Teflon screw (3), M5-Luer-Lock adapters 
(4) in the cap (5) and further M5-Luer-Lock adapters (6) in the bottom. 
 
A programmable logic controller (PLC, Siemens LOGO! 12/14 RC, Siemens AG, Munich, 
Germany) was chosen to control all electronic devices by using the Logo! Soft Comfort software. The 
user panel with display and control buttons enables the control of the program parameters during  
the experiment.  
Purchased parts were made of stainless steel (Luer-Lock connectors, ball bearings), medical grade 
polymers (tubing material), nylon (vessel cannulas), and nitrile butadiene rubber (NBR; O-rings). 
Medical laboratory equipment such as Luer-Locks (VBM Medizintechnik GmbH, Sulz, Germany;  
Hell & Co GmbH, Diespeck, Germany), vessel cannulas (Vieweg GmbH, Kranzberg, Germany), 
syringe filters (Millex-GS, Merck Millipore, Merck KGaA, Darmstadt, Germany), medical tubes 
(Deutsch & Neumann GmbH, Berlin, Germany), and tube connectors (Vieweg GmbH, Kranzberg, 
Germany) are CE marked sterile devices and are therefore qualified for the intended application. 
2.1.2. Sterilization 
The sterilization of the bioreactor is restricted to the components in contact with cells and/or cell 
culture medium; in detail, the seeding cylinder, the scaffold carrier, the reservoir, the tubing system, 
and the adapters. The sterilization was performed by formaldehyde deposition at 60–70 °C for 7 h. 
Samples for sterilization verification were aseptically taken at 24, 72 and 96 h after incubation at  
37 °C/5% CO2, and were screened for contaminations by conventional microbiological evaluation 
methods (Max-von-Pettenkofer-Institut für Hygiene und medizinische Mikrobiologie, University of 
Munich, Munich, Germany). Streak samples on Columbia-Blood agar, Cooked-Blood agar and 
MacConkey agar were incubated for 48 h. Sabouraud agar in slant tubes with an incubation time for  
5 days and liquid triptic soy broth with an incubation time of 10 days were used to detect 
contamination with candida. 
2.1.3. Functionality 
The bioreactor functionality was checked during a standard sequence as described in Sections 2.4.1 
and 2.4.2, in the environment of a standard incubator at 37 °C and 5% CO2. The safe connection of all 
parts and the timed rotation as well as the start of perfusion and pulsation was ensured. The cell media 
a b
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was macroscopically inspected for cloudiness or color change through the transparent housings of the 
reservoir and the seeding device. 
2.2. Scaffold Materials 
Two different scaffold materials were selected for seeding with the bioreactor’s setup: polyurethane 
(PU) and collagen (Figure 6). 
Figure 6. A polyurethane (PU) tube (a; l = 60 mm, d = 6 mm) and a collagen tube  
(b; l = 60 mm, d = 3 mm). 
 
The PU vessel prostheses were manufactured by the ITV-Denkendorf (Denkendorf, Germany) 
using spraying technique [23]. Randomly oriented Polyurethane (PU) fibers offer a mean diameter of 
1.55 µm and form a tube with a wall thickness of 0.3 mm and an inner diameter of 6 mm. For seeding 
purposes PU was γ-sterilized at 10 kGy by a certified service provider for medical device sterilization. 
Collagen tubes manufactured by using bovine origin material were supplied from Viscofan 
Bioengineering (Weinheim, Germany) free of charge. The tubes have an inner diameter of 3 mm and a 
length of 80 mm. 
2.3. Cell Source 
2.3.1. Cell Isolation and Sub Culturing 
ECs and FBs were isolated from remaining saphenous vein segments after bypass operations with 
the informed consent of patients. The average age of the treated patients is 71 years and 80% of them 
are men. Five to 12 cm long pieces of veins were stored at 4 °C in M199 media (Biochrom AG, Berlin, 
Germany) supplemented with 1 mL Penicillin-Streptomycin (5000 U and 5 mg/mL, Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) for a maximum of 5 days until the isolation process. Segments 
were cannulized and rinsed with M199 containing 0.2% heparin (5000 I.E., Ratiopharm GmbH, Ulm, 
Germany) and 0.5% gentamycin (10 mg/mL, Biochrom AG, Berlin, Germany). For EC isolation, veins 
were filled twice with 14 mg collagenase II (280 U, Worthington Biochemical Corporation, 
Lakewood, NJ, USA) soluted in 10 mL 1% HSA (human serum albumin, CLS Behring, Bern, 
Switzerland) and were each incubated for 15 min in PBS (Biochrom AG, Berlin, Germany) under 
physiological conditions in the incubator. Obtained cell suspensions were rinsed out, centrifuged for  
7 min at 500 rpm and finally cultivated in Endothelial Cell Growth Medium (ECGM, Promocell 
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GmbH, Heidelberg, Germany) supplemented with 6% fetal calf serum (Lonza GmbH, Köln, Germany) 
and 0.2% penicillin/streptomycin (Sigma-Aldrich GmbH, Hamburg, Germany) in standard culture flasks 
(T12.5 cm2, Becton Dickinson GmbH, Heidelberg, Germany) at 37 °C/5% CO2. For FB isolation, a 
coverslip method was used. The veins were sliced (1 mm2), transferred into a cell culture dish 
(NuncGmbH& Co.KG, Wiesbaden, Germany), and placed below a coverslip fixed by silicone drops. 
FBs cultivation was performed similarly to ECs using Fibroblast Growth Medium (FGM, Promocell 
GmbH, Heidelberg, Germany) supplemented with 11% fetal calf serum and 0.2% penicillin/streptomycin, 
respectively. The medium was changed every 2–3 days. Cells were passaged at confluency in a ratio of 
1:14 at P1 and in a ratio of 1:3 at P2. 
2.3.2. Cell Characterization 
FBs and ECs were phenotypically characterized by morphological observation and immunocytochemical 
staining (ICC) in eight-well-chamber slides (BD Bioscience, Franklin Lakes, NJ, USA) using specific 
antibodies as previously described [49]. Briefly, vascular cells were stained against EC-specific CD31 
(10.25 μg/mL; Dako Deutschland GmbH, Hamburg, Germany) and FB-specific TE-7 (2 μg/mL, 
Millipore Corporation BioScience Division, Temecula, CA, USA), respectively, according to 
manufacturer’s protocol using EnVision™ + Dual Link System-HRP (Dako Deutschland GmbH, 
Hamburg, Germany). 
2.4. Bioreactor Setups 
2.4.1. Seeding Protocol 
The scaffold tubes—PU or collagen—were clamped to the Luer-Lock adapters in the scaffold carrier 
and were fixed with surgical threads (Ethicon, Johnson & Johnson Medical GmbH, Norderstedt, 
Germany). The seeding device was assembled and filled with FGM. Then FBs (750,000 cells/cm2) 
were applied through the three-way stopcock disposed upstream of the seeding device and colonized 
on the scaffolds lumen by rotation on the mixer according to a defined seeding cycle for 7 h. The cycle 
comprised rotation for 20 s clockwise and 30 s anti-clockwise with a holding phase of 20 min between 
each rotation. The seeding device stops at different points after each rotation phase and allows the cells 
to attach all over the scaffolds surface. 3 days after FB seeding, FGM was replaced by ECGM. ECs 
from the same donor (750,000 cells/cm2) were seeded to the lumen in the same way and cultured for 
another 3 days. Samples were taken for immunohistochemistry (IHC) and scanning electron 
microscopy (SEM). 
2.4.2. Perfusion Protocol 
A preliminary perfusion experiment was performed with PU scaffolds (n = 3). Due to the low 
roughness of the pipe and the low Reynolds number, laminar flow could be assumed. The Reynolds 
number (Re) is based on the mean velocity of the fluid (vm), the hydraulic diameter (Dh) and the 
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The mean velocity of the cell media vm is defined as the volumetric flow rate (?̇?) divided by the pipes 





Dh was 6 mm in the PU tube and the ν of the medium was measured to be about 1 mm2/s. Hence Re 
was between five and 50, while a Re > 2200 is known to cause turbulences in the system. 
Twenty-four hours after FB-seeding with a rotation routine of the seeding cylinder as described 
above, each tube was perfused with a laminar flow of 12 mL/min (shear stress = 100 dyn/cm2) for 2 days. 
After EC-seeding (750,000 cells/cm2), the tubes were similarly perfused. After 6 days in total, the 
tubes were exposed to pulsatile flow conditions by actuating the pulse generator for 24 h. 
After the preliminary perfusion experiments the pump was modified. An optimized perfusion 
protocol was used. The seeding time was reduced to 6 h and the perfusion period was extended to 36 h 
with a smaller and stepwise increase of the shear stress from 10 to 40 dyn/cm2 (flow = 1.27 mL/min to 
5.1 mL/min), as shown in Figure 7. The pulse generator started 24 h after cell seeding with a break of 
24 h of pulsation after EC seeding. Samples were taken for SEM and IHC. 
Figure 7. Perfusion protocol of the conditioned TEVGs. After fibroblast (FB) seeding  
(t = 0 h) the shear stress was gradually raised to 10 dyn/cm2 (t = 6 h) and 20 dyn/cm2  
(t = 24 h). Erythrocytes (ECs) were seeded at t = 48 h and were similarly perfused to FBs. 
The pulsation starts at t = 24 h, stops after ECs seeding and restarts at t = 72 h. After 96 h 
the shear stress was finally raised up to 40 dyn/cm2 for 1 h. 
 
To validate the flow through the scaffold, the pressure was measured at different positions of  
the bioreactor. For all measurements, the pressure transmitter CPT2500 (WIKA GmbH, Klingenberg, 
Germany) was used in combination with the according drivers and software (USBsoft2500) and a 
customized adapter to allow integration of the sensor without influencing the running processes. The 
sensor allows measurements in the range of 0 to 300 mmHg with a deviation of ±3 mmHg and was set 
to a sampling frequency of 100 Hz. A time-frame of 30 s was measured to prevent any measurement 
errors or temporary effects to negatively influence the analysis. Measurements were taken without 
pulsation at flow rates of 10, 20, 40 and 100 dyn and under pulsatile conditions at flow rates of 20, 40 
and 100 dyn. The measurement data was gathered with the USBsoft2500 software (WIKA GmbH, 
Klingenberg, Germany) exported into a umd file and finally processed using Excel 2010 and VBA 
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2.5. Sample Evaluation 
2.5.1. Scanning Electron Microscopy (SEM) 
SEM was used to examine the surface topography of native and seeded scaffolds. Specimens were 
fixed in a solution composed of 456 mL aqua bi-destillated (Ampuwa, Fresenius Kabi Deutschland 
GmbH, Bad Homburg v.d. H., Germany), 0.75 mL 1 N hydrochloric acid (Titrisol, Merck KGaA, 
Darmstadt, Germany), 43.5 mL glutaraldehyd and 5.65 g sodium cocodylatetrihydrate (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) at 4 °C for 24 h at least. Samples were dehydrated in an 
ascending ethanol series (30%, 50%, 70% and 96%) and subsequently in 99.9% ethanol at −20 °C. 
Specimens were dried at the critical point, sputtered with gold for 180 s at 10−5 mbar and analyzed 
using a SEM (EVO® LS 10; Carl Zeiss MikroImaging GmbH, Göttingen, Germany). 
2.5.2. Immunohistochemistry (IHC) 
Immunohistochemical analysis was performed to detect ECs and FBs after scaffold seeding. To this 
end, seeded samples were primarily fixed in 4% formaldehyde (Microcos GmbH, Garching, Germany) 
for 10 days at 4 °C. Fixed samples were paraffin-embedded and sectioned at 5 µm. Slices were stained 
against CD31 (ECs; 10.25 µg/mL; Dako Deutschland GmbH, Hamburg, Germany) and TE-7 (FBs;  
2 µg/mL, Millipore Corporation BioScience Division, Temecula, CA, USA). Antigen retrieval was 
performed in the microwave with antigen retrieval solution at pH 9 (Dako Deutschland GmbH, 
Hamburg, Germany) for CD31 and with EDTA solution at pH 8 for TE-7, respectively. Specimens 
were blocked for endogenous peroxidase and incubated with primary antibody at 4 °C overnight. After 
washing with PBS, samples were covered with biotinylated link for 10 min and HRP Streptavidin-label 
for 10 min according to manufacturer’s protocol (HRP-Detection Kit, Biozol GmbH, Eching, Germany). 
Chromogen labeling was conducted for 10 min using AEC-Peroxidase-Substrate Kit (Vector 
Laboratories Inc., Burlingame, CA, USA). All incubation steps were performed at room temperature of 
20 °C. Cell nuclei were stained with hemalaun (1:4 in PBS; Merck KGaA, Darmstadt, Germany). 
Controls for non-specific binding of chromogen label were performed by excluding the primary 
antibody. A bright field microscope was used to examine all stained samples (Carl Zeiss 
MikroImaging GmbH, Göttingen, Germany). 
3. Results and Discussion 
3.1. Bioreactor Assembly 
BRs for the generation of TEVGs are often bulky systems that require handling by highly trained 
persons [50–52]. 
The new BR is constructed in a way that allows an assembly in a laminar flow cabinet without any 
additional tools like screwdrivers or the need of saturation of the scaffolds to assemble them with the 
BR. As shown in Figure 8a, the novel all-in-one BR consists of six components: a seeding device (1) 
on a mixer (2), a media reservoir (3) a control unit (4) routing the gear motors for the mechanical 
components (2, 5 and 6), a peristaltic pump (5a) with modifiable speed, adjusted through a 
potentiometer (5b), and a pulse generator (6). A great benefit of the bioreactor is the compact assembly 
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of the components on a stable baseplate. This allows for easy and quick handling and transportation, 
which grants stability during the entire experiment with seeding and conditioning processes. 
Figure 8. (a) Rendering of the CATIA data of the all-in-one bioreactor with seeding  
device (1), rotating mixer (2), media reservoir (3), control unit (4), roller pump (5a) with 
potentiometer (5b) and pulse generator (6) and (b) the assembly of the all-in-one bioreactor 
(BR) with connection of all subunits via a simple tubing system. 
 
Figure 9. (a) Sectional view of the seeding cylinder with scaffolds (red), inlet (purple and 
violet), outlet (orange and yellow), spacers (green), Luer-Lock adapters (blue), housing 
(grey) and screw cap (brown); (b) final implementation of the seeding cylinder. 
 
Two TEVGs can be attached to the seeding cylinder (Figure 9) and are connected to the tubing 
system for the perfusion procedure. In contrast to other systems [42,53,54], the dual fixture allows the 
comparison of different scaffold materials under the same settings and the preliminary seeding of the 
scaffolds in the same system lowers effort and vulnerability of the experiments. TEVGs (a, red) are 
located in the cylinder centre and are connected to the media circulation via standard Luer-Lock 
connectors (a, blue, flow in the direction of the blue arrows). The Luer-Lock connectors (a, blue, flow 
in direction of the red arrows) on the bioreactors outlet (a, orange and yellow) allow filling processes 
and media exchange. The scaffold carrier can be adjusted to the length of the TEVG by increasing the 
spacer distance (a, green). For connecting the vessel grafts to the scaffold carrier, the grafts are fixed 
with a surgical thread to the male Luer-Lock adapters with tube connectors. The tube connectors are 
assembled with the female Luer-Lock adapters of the inner parts of the inlet (a, violet) and the outlet 
(a, yellow). Finally, the scaffold carrier is inserted into the scaffolds housing and fixed by screwing the 
cap on top. Manufacturing of the seeding cylinder from PMMA provides optical transparency for 
macroscopic observation of processes within the unit (b). 
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3.2. Bioreactor Sterility 
Culture medium was checked for contamination during the bioreactor run at 24, 72 and 96 h by 
conventional streak samples two times. The microbiological evaluation was performed as previously 
described and showed no microbiological contamination. This indicates the feasibility of long-term 
dynamic studies under sterile conditions. 
3.3. Bioreactor Function 
Luer-Lock adapters with tube connectors ensure an easy connection of the BR components by tubes. 
After filling the BR with media, sterile degasing of the tubing system can be quickly performed 
with a syringe via the three-way stopcocks. Using the three-way stopcock directly in front of the 
seeding device allows an accurate injection of the cell suspension to the scaffold for seeding purposes. 
Pulsatile flow conditioning of the cells raises the tolerance of the tissue-engineered products to 
shear stress, pressure [31,32,55] and thrombotic events [17].  
The pressure measurements show comparable results at the different points of measurement. The 
main focus of interest lies in the flow position inside the graft, measurements were taken directly 
before and after the scaffold. Since these measurements showed similar results, only the measurements 
directly before the scaffold are shown (Table 1, Figure 10). 
The pressure pattern showed similar data (Table 1) for different shear stress forces without 
pulsation while pulsatile flow leads to a pattern near to physiologic conditions in small venoles. 
Figure 10. Pressure pattern for 30 s in the PU scaffold under pulsatile flow with  
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Table 1. Minimal, maximal and average pressure in the polyurethane (PU) scaffold under 
different shear stress values and with or without pulsation of the BR. 
 









10 5.1 5.5 5.4 
20 5.6 5.9 5.8 
40 5.7 6.1 5.9 
100 6.2 6.7 6.5 
With pulsation 
20 2.1 10.6 5.2 
40 2.4 12.5 5.7 
100 3.9 20.5 8.0 
As shown in Figure 8b the seeding device rotates on the mixer to ensure uniform cell seeding all 
over the scaffold’s surface. The media reservoir guarantees a sufficient nutrient supply for the cells 
during cultivation. Gas exchange takes place through the silicone tubes and a sterile filter on top of the 
screw cap. The flow rate can be adjusted by regulating the pump speed during the run with the 
potentiometer. The pump allows a slow increase of the shear stress from 5 dyn/cm2 up to 100 dyn/cm2 to 
enable cell adaption to shear stress and the development of an ECM. The control unit routes a workflow 
to actuate the pump, the pulse generator and the rotating mixer. The roller pump enables a mildly pulsing 
flow through the seeded vascular graft while the pulse generator mimics heartbeat with 60 beats per 
minute as shown in Figure 10. It could be shown that the bioreactor provides sufficient control of the 
flow characteristics inside the scaffold and a pressure-time curve with physiologic characteristics. 
The combination of these features in one BR, which is easy to handle and works properly in a 
standard incubator is unique. 
3.4. Experimental Evaluation of the Bioreactor 
FBs and ECs from the vena saphena magna can be isolated rapidly in large quantities, expanded 
extensively in culture and can be well recovered after repeated freezing/thawing cycles. As previously 
described [56], cells from this source are already used successfully for seeding of PU heart valve 
scaffolds. Peck et al. [57] note that the costs for a TEVG grows with its complexity. The use of ECs 
would reduce time and effort in the production of TEVGs. However, Feugier et al. [58] postulated the 
benefit of coating scaffolds with extra cellular matrix (ECM) proteins to raise ECs adherence. 
Furthermore fibronectin, laminin, and tenascin-C splice variants, proteins of the ECM, are known to 
promote neoangiogenesis and endothelial differentiation [59–61]. FBs are mesenchymal cells and 
synthesize these proteins. Moreover, the adventitia contributes in vascular tone. In this context, 
Laflamme et al. demonstrated that a tissue engineered vascular adventitia, reconstructed with vascular 
fibroblasts derived from human adventitia, has the capability of contraction and relaxing [62].  
The two scaffold materials for cell seeding compared in this study differ in structure and chemical 
composition. SEM analysis (Figure 11) of native PU showed a fine meshwork of polyurethane  
fibers (a), while collagen scaffolds revealed a smooth topography (b). In accordance with results from 
Gulbins et al. [23], seeded PU revealed a cobblestone-morphology (c), indicating the presence of ECs 
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coating. Collagen (d) showed insufficient cell adherence (arrows pointing on attached cells), resulting 
in widely bare scaffold surfaces. 
Figure 11. Scanning electron microscopy (SEM) analysis of polyurethane (a) and  
collagen (b) before (a + b) and after (c + d) rotational seeding. Whilst PU shows cell 
adherence all over the scaffolds surface (c), collagen (d) is seeded only partially (arrows). 
These are representative images of an experiment in triplicates. 
 
In contrast to our findings, Buttafoca et al. [63] could create a complete layer of smooth muscle cells 
within 7 days. But instead of collagen tubes, they used a hybrid of the copolymer P(DLLA-coTMC) 
(D,L-lactide and trimethylene carbonate) and collagen for the purpose of generating a scaffold that is 
more stable than a purely collagen one. So the scaffold possessed a clearly porous surface that might 
have supported the cells adherence. 
In line with the SEM results, a confluent cell layer was detected on the PU scaffolds under 
immunohistochemical examination. Staining against FB-specific TE-7 revealed a confluent coverage 
with FB on PU (Figure 12a). The staining for EC-specific CD31 (c) is partial and weak, indicating that 
ECs lose cell-cell-contacts [64] during static cultivation on PU. 
Collagen (b) did not show positive staining for TE-7 on its surface, indicating the absence of FBs. 
In contrast, ECs were evenly spread on collagen (d) confirming the findings of the SEM analysis. 
While the porous nature of PU supports cell attachment, the smooth surface of collagen seems to 
hamper cell adherence. This might be explained by shear stress during EC-injection to the scaffold’s 
lumen, resulting in the loss of insufficiently attached FBs on collagen.  
As shown in Figure 13, SEM analysis of seeded PU after preliminary perfusion experiments under 
pulsatile flow conditions (100 dyn/cm2) revealed a disrupted cell layer (a). A closer look showed a smooth 
cell surface and an orientation in flow direction after dynamic cultivation. IHC analysis demonstrated a 
partial seeding of PU with slight staining for CD31 (b) and TE-7 (c). Due to these results and the fact 
that the mean shear stress in small venules tends to be from 20 to 40 dyn/cm2 [31], we adapted the 
perfusion protocol. 
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Figure 12. Immunohistochemical (IHC) analysis of dynamically seeded PU and collagen 
after EC-specific CD31 (a + b, red) and FB-specific TE-7 (c + d, red) staining. Positively 
stained cells are highlighted with arrows. Cell nuclei were stained with hemalaun. These 
are representative images of an experiment in triplicates.  
 
Figure 13. SEM (a) and IHC analysis (b = TE-7, c = CD31) of seeded PU after  
flow exposure (100 dyn/cm2) in the bioreactor system show single cells on the surface of 
the scaffolds. 
 
Figure 14. SEM (a) and IHC analysis (b = TE-7, c = CD31) of seeded PU after flow 
exposure (10 to 40 dyn/cm2) in the all-in-one bioreactor system show a confluent and 
flattened lining with ECs (a,c) and FBs (b).These are representative images of an 
experiment in triplicates. 
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Ballermann et al. [31] demonstrated that ECs cultivated for 9 days with 15 dyn/cm2 showed a 
significantly better adherence than cells cultivated under the same conditions with 1 dyn/cm2. Based on 
this finding we started conditioning with a shear stress of 10 dyn/cm2 and then increased it stepwise up 
to 40 dyn/cm2. In contrast to other groups [42,65] we cultivated the cells with an up to 4-fold higher 
shear stress. As shown in Figure 14, SEM analysis of seeded PU revealed a confluent cellular coating 
of the scaffolds (a). After flow exposure, the cell layer is flattened and smoother than under static 
conditions. IHC showed a defined cell multilayer with moderate staining for TE-7 (b) and a high 
expression of CD31 (c). 
4. Conclusions 
The novel BR for the use in a conventional incubator combines seeding and conditioning of two 
vascular prostheses in a unique fashion. It provides a new tool for simultaneous seeding, conditioning 
and perfusion of multiple small-diameter TEVGs. This system allows the development of cell-based 
cardiovascular devices for in vitro evaluation studies as well. 
The results of the first experiments demonstrated a successful and easy sterile process that allows 
cell evaluation within 5 days. This first proof of concept offers further approaches to a routine 
application in TEVG laboratory research processes. Future experiments are still required to evaluate 
the influence of flow and pulse rates on the formation of stable layers on various scaffold materials. 
Additionally, the impact of these parameters on cellular gene expression and scaffolds mechanics has 
to be assessed.  
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